Genetic Testing
CHST14 Gene Ehlers-Danlos Syndrome Musculocontractural Type 1 Genetic Test
This genetic test identifies mutations in the CHST14 gene, associated with Ehlers-Danlos Syndrome, musculocontractural type 1. It uses Next Generation Sequencing (NGS) for accurate analysis.
General information only: This page is not a diagnosis or personal medical advice. A qualified clinician should decide whether testing is appropriate and interpret results in context.
Review status: No completed medical review is recorded for this page.
At a glance
Plan your test
- Sample
- Blood sample (EDTA tube), extracted DNA, or one drop of blood on an FTA card.
- Results
- Approximately 3 to 4 weeks. Confirm with the laboratory before booking.
- Preparation
- A clinical history of the patient is required. A genetic counseling session to create a pedigree chart of affected family members is recommended prior to testing. Confirm with the laboratory before booking.
Payment: M-Pesa and card options can be confirmed during booking.
Insurance & government schemes
Is this test covered for you?
We help you verify whether the CHST14 Gene Ehlers-Danlos Syndrome Musculocontractural Type 1 Genetic Test test can be claimed against your insurer, employer scheme or a Kenyan government health scheme — before you book. Coverage depends on your plan, clinical indication and your provider's rules; final approval always rests with them.
Providers & schemes we can help you check
Government & public schemes
Eligibility and benefits follow the current rules of the Social Health Authority (SHA) and applicable government programmes.
Private insurers & employer schemes
Names shown for identification only — listing does not imply partnership or guarantee of coverage.
Have these ready when we check
- Insurer or scheme name & policy / member number
- A clinician's request / prescription for the test
- Pre-authorisation letter, if your plan requires one
Free coverage check
Ask us to verify your cover
Send your details and our claims team confirms what documents you need and whether pre-authorisation applies — usually the same working day.
Start with fit
Is this the right test for you?
The best test starts with a clear clinical question. These are common reasons a clinician or family may consider this test.
- ✓Individuals with clinical features suggestive of Ehlers-Danlos Syndrome, musculocontractural type 1.
- ✓Family history of Ehlers-Danlos Syndrome or related connective tissue disorders.
- ✓Confirmation of diagnosis in suspected cases.
- ✓Genetic counseling for affected individuals and families.
- ✓Family planning for individuals with a known or suspected CHST14 mutation.
In plain language
What this test helps you understand
This test focuses on identifying changes within the CHST14 gene. This gene provides instructions for making an enzyme important for building certain components of connective tissue. Mutations can disrupt this process, leading to the symptoms associated with EDS, musculocontractural type 1.
Individuals experiencing symptoms suggestive of this type of EDS, such as joint stiffness, contractures, and skin changes, may benefit from this test. It is also recommended for individuals with a family history of EDS or related connective tissue disorders to understand their genetic risk.
Taking this test can provide several benefits, including a definitive diagnosis, guidance for managing the condition, and information for family planning. Understanding the genetic basis of the condition can help healthcare providers tailor appropriate care. Results will be interpreted by genetic counselors and healthcare professionals to explain their significance.
To perform the test, a sample of blood, extracted DNA, or a single drop of blood on an FTA card is required. A detailed clinical history and genetic counseling session, including a family pedigree chart, are essential before testing.
Medical review status
Clinical review pending
A completed medical review is not recorded for this page. No clinician has endorsed the information shown here. Please discuss testing decisions with a qualified healthcare professional.
Meet the DNA Labs Kenya medical team →A simple process
What happens next?
You do not have to navigate the test alone. We help you move from question to next step.
Speak with us
We check the test and answer your questions before collection.
Give your sample
Choose home collection or a coordinated hub visit in Kenya. We explain whether this test uses a cheek swab or blood draw.
Understand your report
A counselor helps you understand the result and the next steps.
Choose your collection
Home collection or a lab visit
We will explain the sample, preparation, and next steps before anything is collected.
Home collection
Choose a coordinated visit at home or another convenient location. Our team confirms the appointment and sample requirements in advance.
Lab or hub visit
Prefer to visit a coordinated location? We can guide you to the right hub and explain what to expect when you arrive.
Ask about locations →Read your report
What common result terms mean
Questions people ask
Frequently asked questions
Collaboration
Open for partnership with hospitals, clinics, doctors & researchers
Whether you are referring patients, building a research programme or supporting students, we work as an extension of your team — with responsive communication and clear scientific standards.
Hospitals & clinics
Referral pathways, coordinated sample logistics and shared reporting that fits your clinical workflow.
Doctors & specialists
LOINC-coded reports, ACMG-based variant classification and a direct scientific line for complex cases.
Research institutions
Sanger sequencing, NGS panels and custom assays — with project design support, batch pricing and agreed turnaround commitments.
Students & academic projects
Discounted laboratory services for college, master's and PhD research projects — including proposal guidance and cost-effective batch testing.
Trust & transparency
Sources, standards & how this page is maintained
Standards & references
- ACMG/AMP technical standards for sequence variant interpretation
- ClinGen curation and gene–disease validity frameworks where applicable
- LOINC-coded reporting for interoperable results
- ISO 9001:2015 quality management; ISO 15189 accreditation in progress
Page provenance
- Last updated: September 27, 2026
- Medical review: not yet completed
- Written for patients & clinicians in Kenya; reviewed periodically against current guidance
Medical disclaimer: this page is general information, not a diagnosis or personal medical advice. Testing decisions and result interpretation should be made with a qualified healthcare professional.
Keep exploring
Related tests
Beta CTx Beta Crosslaps Collagen Type 1 C-Telopeptide Test
The Beta CTx test measures bone resorption markers to help assess bone health and osteoporosis risk.
Learn more →Bcell Rearrangement Detection Test
The Bcell Rearrangement Detection Test helps diagnose leukemia by identifying genetic changes in B cells. It's a key tool for hematologists and oncologists.
Learn more →Dpd Gene Mutations 5Fu Toxicity Detection Test
This genetic test identifies mutations in the DPD gene, helping predict the risk of severe side effects from the chemotherapy drug 5-fluorouracil (5FU).
Learn more →Ganciclovir Resistance Detection Test
This test checks for genetic changes in the cytomegalovirus (CMV) that may make it resistant to the antiviral medication Ganciclovir. It helps guide treatment decisions, especially for patients with weakened immune systems.
Learn more →